• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday

    9/6/22 2:55:25 AM ET
    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Metal Fabrications
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRI alert in real time by email

    Gainers

    • Venus Concept Inc. (NASDAQ:VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.
    • PaxMedica, Inc. (NASDAQ:PXMD) climbed 47.7% to settle at $5.17 on Friday. PaxMedica Executive Chairman, Director Michael Derby reported in Form4 filing the purchase of 95,000 shares at $5.25 per share.
    • Sunrise New Energy Co., Ltd. (NASDAQ:EPOW) gained 31.5% to close at $2.80.
    • Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) jumped 26.9% to close at $2.65.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) gained 23.4% to close at $0.9254. The company, last month, posted a narrower-than-expected quarterly loss.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) jumped 21.7% to close at $2.13.
    • Bright Minds Biosciences Inc. (NASDAQ:DRUG) rose 21.4% to close at $1.93. Bright Minds Biosciences recently initiated dosing in Phase I clinical trial of BMB-101 for Dravet Syndrome.
    • NewAge, Inc. (NASDAQ:NBEV) shares jumped 21.3% to close at $0.1482 on Friday on continued volatility after the company recently announced it filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code. The stock is rebounding after trading lower on Thursday.
    • Liquidia Corporation (NASDAQ:LQDA) gained 20.6% to close at $5.86. Needham maintained Liquidia with a Buy and raised the price target from $12 to $16.
    • Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) surged 18.8% to close at $2.66.
    • Forza X1, Inc. (NASDAQ:FRZA) jumped 18.1% to close at $4.39.
    • United Maritime Corporation (NASDAQ:USEA) rose 17.4% to close at $1.42 after the company announced a $3 million buyback plan.
    • Hollysys Automation Technologies Ltd. (NASDAQ:HOLI) jumped 16.5% to close at $19.76. A consortium led by China's Hollysys Automation’s management aims to take the U.S.-listed automation and control system maker private in a deal at a $1.8 billion valuation, Reuters reported.
    • TScan Therapeutics, Inc. (NASDAQ:TCRX) jumped 16.4% to close at $3.27. TScan Therapeutics, last month, posted a Q2 loss of $0.63 per share.
    • Rain Therapeutics Inc. (NASDAQ:RAIN) rose 15.8% to settle at $5.50.
    • Aurora Innovation, Inc. (NASDAQ:AUR) gained 15.2% to close at $2.43 after the company's CEO reportedly said an Apple or Microsoft takeover was 'potentially appealing'
    • Werewolf Therapeutics, Inc. (NASDAQ:HOWL) jumped 14% to close at $6.93 after the company on Thursday initiated patient dosing in its Phase 1/1b trial of WTX-124.
    • DBV Technologies S.A. (NASDAQ:DBVT) surged 12.9% to close at $2.18. DBV Technologies, last month, posted a Q2 loss of $0.35 per share.
    • Borr Drilling Limited (NYSE:BORR) rose 12.6% to close at $4.46. Shares of several companies in the energy sector traded higher as investors await an OPEC+ meeting next week, in which an oil output cut might be discussed.
    • Smartsheet Inc. (NYSE:SMAR) gained 10.8% to close at $34.16 after the company reported better-than-expected Q2 sales results.
    • Cheetah Mobile Inc.. (NYSE:CMCM) shares gained 10.5% to close at $3.70 following effectiveness of its 1-for-5 reverse split.
    • nCino, Inc. (NASDAQ:NCNO) climbed 9.5% to close at $32.16 after the company reported better-than-expected Q2 adjusted EPS and sales results and issued Q3 and FY23 adjusted EPS and sales guidance above estimates.
    • Helmerich & Payne, Inc. (NYSE:HP) rose 8.5% to close at $44.45. Shares of several companies in the energy sector traded higher as investors await an OPEC+ meeting next week, in which an oil output cut might be discussed. Also, G7 nations agreed on a plan to cap Russian oil prices.
    • AMC Entertainment Holdings, Inc. (NYSE:APE) gained 8.3% to close at $4.97.
    • 5E Advanced Materials Inc. (NASDAQ:FEAM) rose 8.1% to close at $15.99.
    • HighPeak Energy, Inc. (NASDAQ:HPK) gained 8% to close at $26.35.
    • Ampio Pharmaceuticals, Inc. (NYSE:AMPE) rose 7.7% to close at $0.0992 after declining around 9% on Thursday.
    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) gained 7.1% to close at $1.95. The company announced the upcoming launch of un(Think) Awakened Flour.
    • Lululemon Athletica Inc. (NASDAQ:LULU) jumped 6.7% to settle at $314.17 as the company reported better-than-expected results for its second quarter and boosted its annual projections.
    • Okta, Inc. (NASDAQ:OKTA) gained 6.7% to close at $64.63. Guggenheim upgraded Okta from Sell to Neutral.

     

     

    Losers

    • PolyPid Ltd. (NASDAQ:PYPD) shares dipped 73.5% to close at $1.43 on Friday after the company announced its SHIELD I study did not achieve its primary endpoint of reduction in surgical site infections and mortality.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) tumbled 71.6% to settle at $14.90 amid post-IPO volatility.
    • Addentax Group Corp. (NASDAQ:ATXG) fell 68% to close at $9.59. Addentax shares tumbled 95% on Thursday following the company's uplisting and IPO.
    • ShiftPixy, Inc. (NASDAQ:PIXY) dropped 33.9% to settle at $13.60. ShiftPixy recently announced a 1-for-100 reverse stock split.
    • Hempacco Co., Inc. (NASDAQ:HPCO) fell 32.5% to close at $5.64 on post-IPO volatility.
    • Creatd, Inc. (NASDAQ:CRTD) declined 31.1% to settle at $0.3758. Creatd received delist decision and received 15 days to file appeal.
    • Virax Biolabs Group Limited (NASDAQ:VRAX) fell 28.9% to close at $5.64 after jumping 59% on Thursday.
    • Kuke Music Holding Limited (NYSE:KUKE) fell 27.4% to close at $0.82. The company, last month, reported Q2 results.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) declined 23.2% to close at $18.08 after a majority of FDA committee members voted the company's data for AMX0035 is not effective in the treatment of ALS patients.
    • IN8bio, Inc. (NASDAQ:INAB) fell 16.6% to close at $2.41. A Form 4 Filing recently showed Cavu Advisors purchased 51,214 shares at an average price of $2.02.
    • TDH Holdings, Inc. (NASDAQ:PETZ) fell 16.3% to close at $3.70.
    • TDH Holdings recently announced it acquired all of the equity interest of Beijing Wenxin Company from Kargo Services.
    • Calavo Growers, Inc. (NASDAQ:CVGW) dipped 15.9% to close at $35.09 after reporting downbeat Q3 earnings.
    • GigaCloud Technology Inc. (NASDAQ:GCT) fell 15.3% to settle at $20.04.
    • bioAffinity Technologies, Inc. (NASDAQ:BIAF) dipped 15.1% to close at $7.05 after jumping 36% on Thursday. The company priced its IPO at $6.125 per unit.
    • MDJM Ltd (NASDAQ:MDJH) dropped 13.1% to close at $1.86.
    • Reunion Neuroscience Inc. (NASDAQ:REUN) declined 12.7% to close at $3.02.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) fell 11.1% to settle at $1.20.
    • Vivani Medical, Inc. (NASDAQ:VANI) declined 11.1% to close at $3.52.
    • AMTD Digital Inc. (NYSE:HKD) fell 10.9% to close at $100.01.
    • Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) declined 10.3% to close at $24.11. Arcutis Biotherapeutics recently completed the enrollment of subject in its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with Atopic dermatitis (AD).
    • Vera Therapeutics, Inc. (NASDAQ:VERA) declined 10.2% to close at $19.21. Vera Therapeutics, last month, posted a Q2 loss of $0.55 per share.
    • Alpha Tau Medical Ltd. (NASDAQ:DRTS) dropped 9.9% to close at $6.68. Alpha Tau Medical recently posted a Q2 loss of $0.03 per share.
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) fell 9.7% to close at $5.32.
    • Ocugen, Inc. (NASDAQ:OCGN) dropped 8.4% to close at $2.40.
    • Peloton Interactive, Inc. (NASDAQ:PTON) fell 8.2% to close at $9.44. UBS maintained Peloton Interactive with a Sell and lowered the price target from $13 to $8.
    • Lands' End, Inc. (NASDAQ:LE) fell 7.6% to settle at $10.81. Lands' End recently issued Q3 EPS and sales and FY22 EPS guidance below estimates.
    • RiceBran Technologies (NASDAQ:RIBT) fell 5.8% to close at $2.58.
    • NIO Inc. (NYSE:NIO) fell 5.6% to settle at $17.73. Shares of Chinese companies traded lower amid lockdown measures in Chengdu as COVID-19 cases in China rise.
    • Array Technologies, Inc. (NASDAQ:ARRY) fell 5.6% to close at $20.27.
    • Meta Platforms, Inc. (NASDAQ:META) dropped 3.1% to close at $160.32. Meta Platforms agreed to use Qualcomm produced custom chipsets for its Quest virtual reality devices at Berlin's consumer electronics conference, Reuters reported.
    Get the next $AGRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRI
    $AMLX
    $AMPE
    $ARQT

    CompanyDatePrice TargetRatingAnalyst
    Peloton Interactive Inc.
    $PTON
    2/6/2026$8.00 → $6.00Market Perform
    Telsey Advisory Group
    Meta Platforms Inc.
    $META
    1/29/2026$770.00 → $800.00Overweight
    Barclays
    Meta Platforms Inc.
    $META
    1/29/2026$830.00 → $872.00Buy
    UBS
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $850.00Outperform
    Wolfe Research
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $850.00Buy
    Roth Capital
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $825.00Overweight
    Analyst
    Meta Platforms Inc.
    $META
    1/29/2026$754.00 → $849.00Overweight
    Wells Fargo
    Meta Platforms Inc.
    $META
    1/29/2026$840.00 → $880.00Overweight
    Piper Sandler
    More analyst ratings

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stoc

    2/6/26 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TGE's New Film: "Scare Out" - China's First Contemporary National-Security Movie, Set for Lunar New Year Release

    PARIS,  NEW YORK and LONDON, Feb. 6, 2026 /PRNewswire/ -- AMTD Group Inc. ("AMTD Group"), AMTD IDEA Group (NYSE:AMTD, SGX: HKB)), AMTD Digital Inc. (NYSE:HKD) and The Generation Essentials Group (", TGE", , NYSE:TGE, LSE: TGE), a subsidiary of AMTD Digital Inc., jointly announce that TGE latest's release "Scare Out" (the "Movie"), China's first contemporary national-security film created under the guidance of the Ministry of State Security of the People's Republic of China, will debut in theatres during 2026 Lunar New Year, releasing on February 17 in China, the United States, Canada, the United Kingdom, Australia, New Zealand, Singapore, Malaysia, Brunei, Ireland, Fiji, and Papua New Guinea

    2/6/26 8:54:00 AM ET
    $AMTD
    $HKD
    $TGE
    Finance: Consumer Services
    Finance
    Newspapers/Magazines
    Consumer Discretionary

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights01/31/2026 274,852,082  Total gross of voting rights: 274,852,082  Total net* of voting rights: 274,792,237  * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

    2/5/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bep Special Situations Iv Llc bought $8,000,000 worth of shares (4,000,000 units at $2.00) (SEC Form 4)

    4 - 5E Advanced Materials, Inc. (0001888654) (Issuer)

    2/4/26 4:30:07 PM ET
    $FEAM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    CFO Malm Joshua bought $7,500 worth of shares (3,750 units at $2.00), increasing direct ownership by 263% to 5,175 units (SEC Form 4)

    4 - 5E Advanced Materials, Inc. (0001888654) (Issuer)

    2/3/26 4:03:48 PM ET
    $FEAM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    Chief Executive Officer Weibel Paul Wesley Iii bought $7,500 worth of shares (3,750 units at $2.00), increasing direct ownership by 25% to 18,838 units (SEC Form 4)

    4 - 5E Advanced Materials, Inc. (0001888654) (Issuer)

    2/3/26 4:03:16 PM ET
    $FEAM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    SEC Filings

    View All

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Peloton with a new price target

    Telsey Advisory Group reiterated coverage of Peloton with a rating of Market Perform and set a new price target of $6.00 from $8.00 previously

    2/6/26 6:46:09 AM ET
    $PTON
    Recreational Games/Products/Toys
    Consumer Discretionary

    Barclays reiterated coverage on Meta Platforms with a new price target

    Barclays reiterated coverage of Meta Platforms with a rating of Overweight and set a new price target of $800.00 from $770.00 previously

    1/29/26 9:46:59 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    UBS reiterated coverage on Meta Platforms with a new price target

    UBS reiterated coverage of Meta Platforms with a rating of Buy and set a new price target of $872.00 from $830.00 previously

    1/29/26 9:46:59 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Grant Sean was granted 25,000 shares, increasing direct ownership by 27% to 119,130 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:13 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R was granted 10,000 shares, increasing direct ownership by 17% to 67,839 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Skelton Laurence Matthew was granted 20,000 shares, increasing direct ownership by 44% to 65,800 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:11 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Leadership Updates

    Live Leadership Updates

    View All

    PALMETTO APPOINTS LIZ CODDINGTON AS CHIEF FINANCIAL OFFICER

    Peloton CFO brings deep experience scaling consumer and technology-driven businesses to expand access to affordable, reliable energy CHARLOTTE, N.C., Feb. 5, 2026 /PRNewswire/ -- Palmetto, America's leading consumer energy platform, today announced the appointment of Liz Coddington as Chief Financial Officer, effective March 30th, 2026. Coddington will join Palmetto at the close of her four-year tenure as Chief Financial Officer of Peloton Interactive, Inc. (NASDAQ:PTON), where she is currently leading the company's global finance organization during a pivotal period of tran

    2/5/26 8:47:00 AM ET
    $PTON
    Recreational Games/Products/Toys
    Consumer Discretionary

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Okta Names Rob Bernshteyn and Paul Sagan to Board of Directors

    Okta, Inc. (NASDAQ:OKTA), the leading independent identity partner, today announced the appointment of Rob Bernshteyn and Paul Sagan to the Company's board of directors, effective December 19, 2025. "Rob and Paul bring a wealth of operational experience across SaaS, cybersecurity, and AI that will help drive Okta's next phase of growth," said Todd McKinnon, Okta CEO and Co-Founder. "Their expertise comes at a pivotal moment, as identity becomes the foundation for secure AI. With their leadership, we'll continue strengthening Okta's position as the neutral identity partner and accelerating our work to help customers safely adopt AI agents." "Okta has proven that identity is critical to sec

    12/19/25 4:01:00 PM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Financials

    Live finance-specific insights

    View All

    Peloton Announces Q2 FY2026 Financial Results

    Delivered Year-over-Year Improvement in Profitability While Investing in Ambitious Innovation Agenda Raises Full Year FY2026 Adjusted EBITDA Guidance to $450 - $500 million* NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. today reported financial results for the quarter ended December 31, 2025. Q2 FY2026 Financial Highlights Ending Paid Connected Fitness Subscriptions were 2.661 million, a decrease of 214,000 or 7% year-over-year and 6,000 above the midpoint of our guidance range. We observed better-than-expected Average Net Monthly Paid Connected Fitness Subscription Churn following Membership price increases announced on October 1, which was partially offset by l

    2/5/26 7:00:00 AM ET
    $PTON
    Recreational Games/Products/Toys
    Consumer Discretionary

    Helmerich & Payne, Inc. Announces Fiscal First Quarter Results

    Helmerich & Payne, Inc. (NYSE:HP) Operating and Financial Highlights for the Quarter Ended December 31, 2025 The Company reported consolidated net loss of $(97) million, or $(0.98) per share, which includes the impact of a non-cash impairment charge of $103 million. Adjusted for this and other non-recurring one-time items, adjusted earnings(1) were $(14) million, or $(0.15) per share. North America Solutions (NAS) reported operating income of $36 million for the quarter, compared with $118 million in the prior quarter. These results include a one-time impairment of $98 million. NAS generated direct margins(2) of $239 million, resulting in direct margin(2) per day of $18,193, reflect

    2/4/26 4:05:00 PM ET
    $HP
    Oil & Gas Production
    Energy

    ARRAY Technologies Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    ALBUQUERQUE, N.M., Feb. 04, 2026 (GLOBE NEWSWIRE) -- ARRAY Technologies, Inc. (the "Company" or "ARRAY") (NASDAQ:ARRY), a leading global provider of solar tracking technology products, software, services and foundation solutions, today announced that the Company will release its fourth quarter and full year 2025 results after the market closes on Wednesday, February 25, 2026, to be followed by a conference call at 5:00 p.m. (Eastern Time) that same day. The conference call can be accessed live over the phone by dialing (877)-869-3847 (domestic) or (201)-689-8261 (international), or via webcast of the live conference call by logging onto the Investor Relations section of the Company's webs

    2/4/26 4:05:00 PM ET
    $ARRY
    Miscellaneous manufacturing industries
    Consumer Discretionary

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by nCino Inc.

    SC 13D/A - nCino, Inc. (0001902733) (Subject)

    12/12/24 6:29:06 PM ET
    $NCNO
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13D/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/9/24 5:54:19 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate